Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11390726rdf:typepubmed:Citationlld:pubmed
pubmed-article:11390726lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0019004lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C1524112lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0302583lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0060241lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0220836lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0117571lld:lifeskim
pubmed-article:11390726lifeskim:mentionsumls-concept:C0529374lld:lifeskim
pubmed-article:11390726pubmed:issue6lld:pubmed
pubmed-article:11390726pubmed:dateCreated2001-6-6lld:pubmed
pubmed-article:11390726pubmed:abstractTextThe objectives of the present trial were to compare the efficacy and safety of two i.v. iron preparations with respect to haemoglobin levels, iron status and recombinant human erythropoetin (rHuEpo) dosage requirements in stable, rHuEpo-treated haemodialysis patients (maintenance phase of iron treatment) over 6 months.lld:pubmed
pubmed-article:11390726pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:languageenglld:pubmed
pubmed-article:11390726pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:citationSubsetIMlld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11390726pubmed:statusMEDLINElld:pubmed
pubmed-article:11390726pubmed:monthJunlld:pubmed
pubmed-article:11390726pubmed:issn0931-0509lld:pubmed
pubmed-article:11390726pubmed:authorpubmed-author:MatzkiesFFlld:pubmed
pubmed-article:11390726pubmed:authorpubmed-author:TeschnerMMlld:pubmed
pubmed-article:11390726pubmed:authorpubmed-author:BahnerUUlld:pubmed
pubmed-article:11390726pubmed:authorpubmed-author:SchaeferR MRMlld:pubmed
pubmed-article:11390726pubmed:authorpubmed-author:KoschMMlld:pubmed
pubmed-article:11390726pubmed:authorpubmed-author:BettgerHHlld:pubmed
pubmed-article:11390726pubmed:issnTypePrintlld:pubmed
pubmed-article:11390726pubmed:volume16lld:pubmed
pubmed-article:11390726pubmed:ownerNLMlld:pubmed
pubmed-article:11390726pubmed:authorsCompleteYlld:pubmed
pubmed-article:11390726pubmed:pagination1239-44lld:pubmed
pubmed-article:11390726pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:meshHeadingpubmed-meshheading:11390726...lld:pubmed
pubmed-article:11390726pubmed:year2001lld:pubmed
pubmed-article:11390726pubmed:articleTitleA randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.lld:pubmed
pubmed-article:11390726pubmed:affiliationDepartment of Internal Medicine D, University of Münster, Albert-Schweitzer-Str. 33, D-48129 Münster, Germany.lld:pubmed
pubmed-article:11390726pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11390726pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11390726pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11390726pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11390726lld:pubmed